Evenity™ (romosozumab-aqqg)

Evenity is covered only for postmenopausal women with osteoporosis at high fracture risk (osteoporotic/fragility fracture, T‑score ≤ −2.5, or T‑score −1.0 to −2.5 with high‑risk features) who have failed, are intolerant of, or cannot take other osteoporosis therapies (including documented 12‑month oral bisphosphonate trial or prior IV bisphosphonate use, or severe renal impairment/CrCl <35 mL/min); required documentation includes diagnosis, BMD/T‑scores with site, fracture history, prior bisphosphonate details or intolerance/contraindication evidence, and renal function. Dosing is limited to 210 mg subcutaneously once monthly for a single 12‑month course per lifetime, and requests not meeting these criteria are excluded.

"Maximum of 12 monthly doses during a single therapy course; treatment duration is 12 monthly doses."

Sign up to see full coverage criteria, indications, and limitations.